Key result
PAH incurs a heavy economic burden with ~3 annual hospital admissions per patient.
Why the study?
The clinical and economic burden of pulmonary arterial hypertension is poorly understood outside the United States.
Population
2527 adult patients with PAH in England
Design
Retrospective database study
Authors
Loading...
PAH imposes heavy costs in England; leaves open whether targeted therapies can reduce admissions and should not yet change practice.
Cohort (n=2,527)
Yes
Pulmonary arterial hypertension imposes a substantial economic and healthcare resource burden in England, driven primarily by inpatient admissions and outpatient visits.
Exposto et al. (2021) conducted a cohort in Pulmonary arterial hypertension (n=2,527). Pulmonary arterial hypertension was evaluated on Healthcare resource utilisation (HCRU) and associated costs. Pulmonary arterial hypertension in England incurred a heavy economic burden, with mean annual admission rates of 2.9 to 3.2 per patient and total costs of £43.2 million from 2013 to 2017.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: